search

Active clinical trials for "Stevens-Johnson Syndrome"

Results 11-20 of 31

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

Chemical InjuriesUnspecified Complication of Corneal Transplant7 more

The purpose of the pilot study is to test the efficacy and safety of riboflavin/Ultraviolet A (UVA) cross-linked human donor corneas as carriers for the Boston Keratoprosthesis (Boston KPro) in patients with higher risk for corneal melting (keratolysis).

Completed17 enrollment criteria

Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye...

Stevens-Johnson Syndrome

The purpose of this study is to evaluate the efficacy of 0.05% cyclosporin ophthalmic emulsion (Restasis) in patients with Stevens-Johnson syndrome that have dry eyes by subjective symptoms and signs.

Completed18 enrollment criteria

G-CSF in the Treatment of Toxic Epidermal Necrolysis

Stevens - Johnson Syndrome

NeupoNET aims to evaluate interest of G-CSF in the treatment of Toxic Epidermal necrolysis. This is a prospective randomized controlled trial. Patients will be allocated in a treatment group (receiving an injection of 5 microg/kg/d of G-CSF during 5 consecutive days) or in a placebo group. Patients will be randomized at admission and will be followed until 3 months after discharge.

Completed9 enrollment criteria

Salivary Gland Transplantation in the Treatment of Dry Eye in Patients With Stevens-Johnson Syndrome....

SymblepharonDry Eye2 more

The purpose of this study is to evaluate salivary gland and labial mucous membrane transplantation in patients with severe symblepharon and dry eye secondary to Stevens-Johnson Syndrome (SJS).

Completed3 enrollment criteria

Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation

PterygiumOcular Surface Disease2 more

To evaluate the use of cultivated conjunctival epithelial equivalents for the treatment of ocular diseases

Completed14 enrollment criteria

Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)

Toxic Epidermal Necrolysis

To determine whether treatment of patients who have toxic epidermal necrolysis with a drug called remicaide increases the number of patients who are alive 30 days laters.

Withdrawn7 enrollment criteria

Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis

Toxic Epidermal Necrolysis

The primary objectives of this study are to investigate the efficacy and safety of topical steroid ointment (clobetasol 0.05%) for the treatment of the cutaneous manifestations of toxic epidermal necrolysis (TEN).

Withdrawn17 enrollment criteria

Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis...

Graft vs Host DiseaseCongenital Aniridia3 more

The ARGOS-IO pressure sensor is intended to be implanted in the human eye in combination with Boston Keratoprosthesis (BKPro) surgery and to remain in place indefinitely. It is intended to be used together with the hand-held Mesograph reading device to telemetrically measure the intraocular pressure (IOP) of patients with a BKPro. The purpose of this study is to evaluate the safety and performance of the ARGOS-IO system in patients undergoing concomitant implantation of a BKPro and an ARGOS-IO sensor over the 12 month period beginning at implantation.

Completed20 enrollment criteria

Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson...

Stevens-Johnson SyndromeCorneal Blindness

The proposed study is intended to test the idea, based upon current knowledge of the biology and physiology of corneal ulceration in SJS/TENS patients who receive a keratoprosthesis, and on the known effects of infliximab on matrix metalloproteinases, that infliximab therapy for such patients may reduce the likelihood of corneal ulceration, and hence extend the period of prosthesis retention and vision recovery.

Withdrawn33 enrollment criteria

Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions...

Toxic Epidermal Necrolysis

The purpose of this study is to determine whether isotretinoin is helpful in treating patients with an adverse cutaneous drug eruption known as toxic epidermal necrolysis (TEN).

Withdrawn17 enrollment criteria

Need Help? Contact our team!


We'll reach out to this number within 24 hrs